eligibility_summary
Eligible: 18–80 with unresectable/metastatic epithelial cancer (e.g., NSCLC, liver), post/unsuitable for SOC, GPC3 IHC ≥50% (≥1+), measurable lesion, survival ≥90 d, adequate organ function (marrow, liver, renal, coagulation) consent/contraception. Exclude: pregnancy/lactation, recent therapy/trial, major CV/cerebrovascular/thromboembolic disease, QTcF>480, active HBV/HCV/HIV, autoimmune disease, CNS mets, ILD/severe lung disease, uncontrolled effusions, severe drug allergy, unresolved toxicities.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial tests REVO-UWD-03, an allogeneic “universal” CAR-T cell therapy (biologic, donor-derived, gene‑modified T cells) targeting glypican‑3 (GPC3). The CAR’s antigen-binding domain recognizes GPC3 on tumor cells, triggering T‑cell activation and cytotoxic killing (perforin/granzyme and cytokine release), aiming to eliminate GPC3+ lesions in advanced hepatocellular carcinoma and NSCLC. Patients receive single-dose CAR‑T after lymphodepleting chemotherapy (typically fludarabine [antimetabolite] and cyclophosphamide [alkylating agent]). Targets: GPC3-expressing tumor cells (cell-surface heparan sulfate proteoglycan), engages T‑cell effector pathways.